IInsulet develops insulin delivery systems for diabetes. Its flagship Omnipod is a tubeless, waterproof insulin pump that delivers continuous insulin, controlled by a wireless handheld device and using disposable pods. The company also offers Omnipod 5, an automated insulin delivery system that works with continuous glucose monitors to adjust dosing. Insulet differentiates itself with a tubeless design and global manufacturing and distribution, aiming to make insulin delivery more convenient and autonomous for users.
Work here?Claim your company
Industries
Company Size
5,001-10,000
Company Stage
IPO
Headquarters
Acton, MA
Founded
2000
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Total Funding
$591.8M
Above
Industry Average
Funded Over
7 Rounds
Tandem Diabetes Care wins FDA clearance for tubeless Mobi set worn up to 7 days. The new supplies work with existing pumps, with a U.S. launch planned for the first half of 2027 and access limited to pharmacy benefits. Tubeless infusion-set wear of up to seven days has received U.S. Food and Drug Administration clearance as Tandem Diabetes Care, Inc. NASDAQTNDM announced on Friday new Mobi supplies compatible with its existing pump. Full U.S. commercial launch is planned for the first half of 2027. The system's Control-IQ+ software is labelled for type 1 diabetes from age two and type 2 diabetes from age 18. According to Tandem's product page, the tubeless infusion set is cleared for up to seven days of wear, while the insulin cartridge is cleared for three days of use. Tandem is a San Diego-based global diabetes-device manufacturer that sells automated insulin-delivery pumps. The clearance adds a tubeless option to Mobi while preserving the option to use tubing. Shares closed at US$17.51 on Nasdaq at 4:00 p.m. EST on Nov. 12, according to NASDAQTNDM, before Friday's clearance announcement. Customers with an in-warranty Mobi will not need a replacement pump to use the new supplies, according to the Nov. 13 release. Existing pumps are already compatible, so access for those customers depends on obtaining the new cartridge and infusion set. "The Tandem Mobi insulin pump was originally designed to make different wear options possible, which now includes a tubeless option with up to 7 days of wear," chief executive John Sheridan said in the release. Mobi uses continuous glucose monitor readings to predict glucose levels 30 minutes ahead and automatically adjust insulin delivery. The prescription-only system still requires active diabetes management, Tandem cautions. Insulet offers up to three days of tubeless delivery. The direct tubeless competitor is Insulet Corporation NASDAQPODD, whose Omnipod 5 product page, checked Nov. 13, describes up to three days of automated insulin delivery. Its labelled population also includes people with type 1 diabetes from age two and adults with type 2 diabetes. Omnipod 5 is available through the pharmacy, according to Insulet's product page. Tandem is entering that channel with a longer infusion-site wear interval, although its three-day cartridge limit means the insulin supply still needs more frequent attention. The incumbent's sales show the scale of the market Tandem is targeting. Insulet reported on Nov. 4 that U.S. Omnipod revenue reached US$570.4 million in the third quarter, up 14.7 per cent from a year earlier. Infusion-set wear of up to seven days is already part of another listed pump maker's offering. MiniMed Group Inc. NASDAQMMED said on March 18 that its FDA-cleared Flex system supports an extended infusion set with up to seven days of wear. The distinction for Tandem is the combination of tubeless delivery and the longer site-change interval. Its announcement concerns a new way to wear an existing pump, rather than a requirement for current eligible customers to buy new hardware. Pharmacy coverage limits initial access. The new Mobi tubeless cartridges and infusion sets will be available exclusively through pharmacies to customers with pharmacy benefits. Tandem estimated in its Nov. 13 release that pharmacy coverage for Mobi customers was available for approximately 50 per cent of insured U.S. lives. That estimate describes insurance coverage, rather than the number of patients using Mobi or orders for the new supplies. Tandem expects coverage to expand before launch and throughout 2027, while warning that scaling and infrastructure challenges could delay availability. The next commercial milestone is the planned U.S. launch in the first half of 2027. It will make the cleared tubeless supplies available to eligible customers, with pharmacy access determining who can obtain them.
Insulet, Marvel Comics smash diabetes stigma with new Omnipod-powered superhero. Insulet's squad of friendly neighborhood diabetes superheroes is assembling. The newest superhero born out of a collaboration with Marvel Comics and Insulet, Gluconaut is armed with the strength of the stars and Insulet's insulin delivery pump Omnipod to show others with diabetes that they too can be a confident hero while managing their glucose. The new comic rolled out Nov. 10 and builds on Insulet's initial Marvel collab "Dyasonic: Sound of Strength," which features another Omnipod-powered superhero. Where Dyasonic laid the foundation of "a new generation of diabetes heroes," as Insulet put it in a release, Gluconaut shines a light on a stigma-busting message of self-confidence and strength. After distributing thousands of copies of "Dyasonic: Sound of Strength" to HCPs and diabetes patients around the globe, the response was "great," chief growth officer Manoj Raghunandanan explained to Fierce. But the community wanted more, telling Insulet "pretty directly, 'we want to see more of ourselves in this,'" the exec said. Enter Podrick, the hero character in "Gluconaut: Strength of Stars." Podrick is a high schooler with type 1 diabetes who worries about fitting in while wearing his medical device. It isn't until Podrick meets a Skrull, an extraterrestrial shapeshifter familiar to Marvel fans, that he connects with someone who "knows exactly what it's like to feel different," Raghunandanan said. Through the powerful force of inner self-acceptance and Insulet's Omnipod, Podrick rises to hero status as Gluconaut, gaining confidence in managing his diabetes along the way. The story was written by Pallie Paul Allor, who lives with diabetes. This is important, as the diabetes community "can tell in about two pages whether the writer has lived it," Raghunandanan noted. Allor's own experience brings an authentic voice to the story and can inspire readers to embrace their own diabetes without fear of judgement. According to an Insulet survey, diabetes representation remains crucial for the community, with over half of those with type 1 diabetes surveyed in the U.S. highlighting the importance of seeing their condition accurately represented in culture and media, according to the company. Still, many are missing out on that representation, with 37% reporting that they rarely see it and 14% marking that they never do. Meanwhile, one in three people surveyed say they have "hidden" their condition, Insulet CEO Ashley McEvoy commented in a statement. "That's a reminder that representation matters," McEvoy continued. "We continue our work with Marvel because stories can shape beliefs and spark understanding in ways facts alone cannot. Our new hero, Gluconaut, builds on the impact of Dyasonic, helping young people with diabetes see themselves as empowered by what's possible and not limited by their condition." Survey respondents explained they hide their condition due to fear of being judged and "not wanting to explain it over and over," Raghunandanan elaborated. And for teenagers specifically, "being seen as different is about the hardest thing there is." Podrick's arc is built to address this and other learnings from the survey. "That's really what we're after," Raghunandanan said. "If a kid reads this and thinks, okay, maybe I could wear one of these, that opens the door to technology that has the potential to improve outcomes and quality of life." Along with the Marvel collab, Insulet is teaming up with non-profit organization Children with Diabetes (CWD) and spreading the Gluconaut story across channels by encouraging community members and supporters to share Gluconaut GIFs on social media. Insulet will, in turn, provide scholarships for families to attend CWD's Friends for Life conferences in Orlando, it said. The company and CWD ran a similar partnership for Dyasonic, with Insulet donating $1 to the non-profit for every Instagram post that includes a Dyasonic GIPHY or sticker. From comic books to TV screens, Insulet's efforts to push diabetes representation into the mainstream have resulted in a string of unique partnerships over the years. Most recently, Omnipod made its paid integration TV debut on the 2026 revival of medical comedy "Scrubs" as part of a plotline surrounding an annual barbecue party. In the episode, the show's chief of surgery Christopher Turk (played by actor Donald Faison), explains that he can still enjoy barbecue sauce and other meals thanks to his Omnipod wearable. The Omnipod shout-out marked a "milestone moment" that brings diabetes representation to millions of Disney and ABC's "Scrubs" viewers, Insulet's director of U.S. consumer marketing Lucas Escobar explained at the time. Each of Insulet's creative tie-ups, whether it be "Scrubs," diabetes-focused mindfulness techniques through the Calm app or an official Omnipod Mango color with Pantone, serves a different purpose. The Marvel collab, for its part, "gives a kid with diabetes a hero who looks like them, and because it's Marvel, kids are excited to read it," Raghunandanan said. Insulet also uses the campaigns to normalize Omnipod throughout culture, as the more "normal" the device appears, "the easier it is to live with," he noted. Insulet's Omnipod 5 tubeless insulin pump became the first automated insulin delivery system to win FDA approval for both Type 1 and Type 2 diabetes management after snagging an FDA expansion in Type 2 diabetes in 2024, building on its initial Type 1 nod from 2022. The Omnipod system automatically delivers insulin injections as needed and can pair with a phone app to make continuous insulin delivery easier, a key feature highlighted in the "Scrubs" episode. Brand integration has "always been central to how we build Omnipod as a category leader," Raghunandanan explained in a statement earlier this year. So far in 2026, Insulet's Omnipod products have generated $2.4 billion in global revenue, the company recently reported. Insulet isn't the first in the medical space to open the books on a Marvel Comics partnership. Even as far back as a decade ago, comic book characters who fight crime while battling different medical conditions have spawned to stir up positive representation, as evident in Takeda's 2016 Marvel comic featuring inflammatory bowel disease-suffering hero Samarium. In 2022, Pfizer and BioNTech added "Everyday Heroes" to Marvel's Avengers squad to help boost vaccine uptake and beat COVID, which was characterized as the supervillain Ultron in the comic.
Insulet (NASDAQ:PODD) releases quarterly earnings results, beats expectations by $0.40 EPS. Insulet (NASDAQ:PODD - Get Free Report) posted its quarterly earnings results on Wednesday. The medical instruments supplier reported $1.99 earnings per share for the quarter, beating analysts' consensus estimates of $1.59 by $0.40, FiscalAI reports. The firm had revenue of $842.00 million for the quarter, compared to the consensus estimate of $832.63 million. Insulet had a return on equity of 29.29% and a net margin of 12.29%. The company's revenue for the quarter was up 19.2% compared to the same quarter last year. During the same period in the previous year, the business earned $1.24 earnings per share. Here are the key takeaways from Insulet's conference call: * Third-quarter revenue rose 19.6% in constant currency to $842 million, supported by more than 20% growth in the global customer base. Adjusted operating margin expanded 490 basis points, and adjusted EPS increased 60% year over year. * Insulet raised its 2026 outlook to the high end of its prior range, expecting 21%-22% constant-currency revenue growth and more than 30% adjusted EPS growth. It also expects approximately 150 basis points of adjusted operating margin expansion. * Management expects 2027 revenue growth to be modestly below its prior mid-teens framework, with U.S. growth toward the lower end of its earlier range and international growth moderating meaningfully. The company cited tougher comparisons, less international price-mix benefit, new competition, and limited near-term contributions from launches. * Insulet reported modest improvement in type 2 customer retention after changes to sampling, onboarding, sales incentives, and customer support. Its Omnipod Discover platform has been adopted by more than 35,000 users and 5,000 clinicians, though management said the impact of these efforts will build over time. * The board approved a $1 billion increase to the share repurchase authorization, with $400 million planned for repurchases in the fourth quarter using cash on hand. Insulet trading up 3.6%. Shares of PODD traded up $5.63 on Wednesday, hitting $160.49. 1,369,811 shares of the stock traded hands, compared to its average volume of 1,392,058. Insulet has a 1 year low of $126.40 and a 1 year high of $354.88. The stock's 50 day moving average is $141.21 and its two-hundred day moving average is $178.61. The firm has a market capitalization of $11.13 billion, a P/E ratio of 30.00, a P/E/G ratio of 1.21 and a beta of 1.06. The company has a quick ratio of 1.83, a current ratio of 2.48 and a debt-to-equity ratio of 0.65. Wall Street analysts forecast growth. Several equities analysts recently weighed in on the company. Wall Street Zen downgraded Insulet from a "buy" rating to a "hold" rating in a research note on Saturday, October 24th. BTIG Research cut Insulet from a "buy" rating to a "neutral" rating in a report on Thursday, August 6th. JPMorgan Chase & Co. downgraded Insulet from an "overweight" rating to a "neutral" rating and reduced their price objective for the company from $275.00 to $152.00 in a research report on Thursday, August 6th. Leerink Partners lowered Insulet from an "outperform" rating to a "market perform" rating and decreased their price objective for the company from $247.00 to $145.00 in a research note on Thursday, August 6th. Finally, Wells Fargo & Company cut Insulet from an "overweight" rating to an "equal weight" rating and dropped their price objective for the stock from $255.00 to $144.00 in a research report on Wednesday, August 5th. Thirteen analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, Insulet currently has a consensus rating of "Hold" and an average target price of $186.68. Insulet news summary. Here are the key news stories impacting Insulet this week: * Insulet reported Q3 adjusted earnings of $1.99 per share, topping the $1.59 consensus estimate. Revenue increased 19.2% year over year to $842 million, also ahead of expectations, with reports citing stronger net income and margin expansion. * The company announced a $1 billion share buyback, which could support demand for shares and signals management's willingness to return capital to investors. * Insulet maintained its 2026 EPS outlook, providing continuity but no increase to the earnings forecast in the cited report. Insulet company profile. Insulet Corporation is a medical device company that develops, manufactures and sells wearable, tubeless insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps. The company's primary product platform is Omnipod, which includes the disposable, wearable Pod and a handheld controller or compatible smartphone-based application. Omnipod products include the Omnipod DASH system and the Omnipod 5 Automated Insulin Delivery System, which is designed to integrate with compatible continuous glucose monitoring technology to help automate insulin delivery. Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.
Insulet Corp., the Acton, Massachusetts-based maker of insulin infusion systems, reported third-quarter net income of $141.1 million, or $2.03 per share. Adjusted for one-time gains and costs, earnings were $1.99 per share. Eight analysts surveyed by Zacks Investment Research had expected $1.59. Revenue was $842 million, also above forecasts. Seven analysts had expected $833.3 million.
Insulet reported third-quarter revenue of $842.0 million, up 19.2% from a year earlier. Growth was 19.6% in constant currency, slightly above the top of the company's guidance range. Omnipod revenue rose 19.7% to $836.6 million. US sales grew 14.7% to $570.4 million, while international sales climbed 31.7% to $266.2 million. Net income reached $141.1 million, or $2.03 per diluted share, compared with $87.6 million, or $1.24 per share, a year earlier. Operating income was $189.8 million, or 22.5% of revenue. The board approved a $1 billion share repurchase programme. Insulet expects to spend about $400 million on buybacks in the fourth quarter of 2026, funded with existing cash.
Find jobs on Simplify and start your career today
Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs
Industries
Company Size
5,001-10,000
Company Stage
IPO
Headquarters
Acton, MA
Founded
2000
Find jobs on Simplify and start your career today
Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs